Patents Assigned to the Secretary, Department of
-
Patent number: 11938177Abstract: Embodiments of a novel platform for delivering a peptide antigen to a subject to induce an immune response to the peptide antigen are provided. For example, nanoparticle polyplexes are provided that comprise a polymer linked to a peptide conjugate by an electrostatic interaction. The conjugate comprises a peptide antigen linked to a peptide tag through an optional linker. An adjuvant may be included in the nanoparticle polyplex, linked to either the polymer or the conjugate, or admixed with the nanoparticles. The nanoparticle polyplex can be administered to a subject to induce an immune response to the peptide antigen.Type: GrantFiled: November 2, 2021Date of Patent: March 26, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Robert Seder, Geoffrey Lynn
-
Patent number: 11939365Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated human p53. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: GrantFiled: September 17, 2018Date of Patent: March 26, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Drew C. Deniger, Steven A. Rosenberg, Anna Pasetto, Rami Yoseph, Winifred M. Lo, Yong-Chen Lu, Maria R. Parkhurst, Paul F. Robbins, Parisa Malekzadeh
-
Patent number: 11939356Abstract: Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.Type: GrantFiled: March 15, 2021Date of Patent: March 26, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Kwong, Ivelin Georgiev, Michael Gordon Joyce, Masaru Kanekiyo, Aliaksandr Druz, Ulrich Baxa, Joseph Van Galen, Cheng Cheng, John Mascola, Yaroslav Tsybovsky, Yongping Yang, Barney Graham, Syed Mohammad Moin, Jeffrey Boyington
-
Patent number: 11938221Abstract: Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus. The fusion proteins self-assemble to form nanoparticles that display a heterogeneous population of immunogenic portions on their surface. When administered to an individual, such nanoparticles elicit an immune response to different strains, types, subtypes and species with in the same taxonomic family. Thus, such nanoparticles can be used to vaccinate an individual against infection by different Types, subtypes and/or strains of infectious agents.Type: GrantFiled: November 4, 2021Date of Patent: March 26, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Barney S. Graham, Masaru Kanekiyo, Hadi M. Yassine
-
Publication number: 20240084008Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: ApplicationFiled: November 6, 2023Publication date: March 14, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Rimas J. Orentas, Ira H. Pastan, Dimiter S. Dimitrov, Crystal L. MacKall
-
Publication number: 20240084007Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: ApplicationFiled: November 6, 2023Publication date: March 14, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Rimas J. Orentas, Ira H. Pastan, Dimiter S. Dimitrov, Crystal L. MacKall
-
Publication number: 20240082177Abstract: The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.Type: ApplicationFiled: November 10, 2023Publication date: March 14, 2024Applicants: MESHABERASE, LLC, The United States of America, as Represented by the Secretary, Department of Health & Human ServicesInventors: Benjamin Rubin, Mark Gilbert, Jinkyu Jung
-
Patent number: 11926656Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus (EBV) infection in mammals, and methods of using those compositions of matter for the detection, diagnosis and treatment of EBV infection are described. Also described are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.Type: GrantFiled: December 16, 2021Date of Patent: March 12, 2024Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Wei Bu, Masaru Kanekiyo, Michael Gordon Joyce, Jeffrey I. Cohen
-
Patent number: 11925664Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.Type: GrantFiled: June 12, 2020Date of Patent: March 12, 2024Assignees: INTIMA BIOSCIENCE, INC., REGENTS OF THE UNIVERSITY OF MINNESOTA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Branden Moriarity, Beau Webber, David Largaespada, Modassir Choudhry, Steven A. Rosenberg
-
Patent number: 11925558Abstract: Devices and methods are disclosed for the treatment or repair of regurgitant cardiac valves, such as a mitral valve. An annuloplasty device can be placed in the coronary sinus to reshape the mitral valve and reduce mitral valve regurgitation. A protective device can be placed between the annuloplasty device and an underlying coronary artery to inhibit compression of the underlying coronary artery by the annuloplasty device in the coronary sinus. In addition, the protective device can inhibit compression of the coronary artery from inside the heart, such as from a prosthetic mitral valve that exerts radially outward pressure toward the coronary artery. The annuloplasty device can also create an artificial inner ridge or retaining feature projecting into the native mitral valve region to help secure a prosthetic mitral valve.Type: GrantFiled: May 26, 2020Date of Patent: March 12, 2024Assignee: The United States of America, As Represented By The Secretary, Department of Health and Human ServicesInventors: June-Hong Kim, Robert J. Lederman, Ozgur Kocaturk
-
Patent number: 11921181Abstract: Provided herein are methods and systems for high-resolution, cerebrospinal fluid-suppressed T2*-weighted magnetic resonance imaging of cortical lesions.Type: GrantFiled: April 24, 2020Date of Patent: March 5, 2024Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Daniel Salo Reich, Erin Savner Beck, Govind Nair, Neville Dali Gai
-
Patent number: 11918639Abstract: The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.Type: GrantFiled: October 11, 2021Date of Patent: March 5, 2024Assignees: Bavarian Nordic A/S, Janssen Vaccines & Prevention B.V., The United States of America, as represented by The Secretary, Department of Health and Human ServiceInventors: Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier, Maria Grazia Pau, Benoit Christophe Stephan Callendret, Lucy A. Ward
-
Patent number: 11918640Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.Type: GrantFiled: June 13, 2022Date of Patent: March 5, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Christian S. Hinrichs, Steven A. Rosenberg
-
Patent number: 11918638Abstract: Reported herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype in which the native positions of the NS1 and/or NS2 genes in the RSV genome are shifted to a higher position, that is at positions that are more distal to the promoter. The changes in the gene positions may be present in combination with mutations at other loci to achieve desired levels of attenuation and immunogenicity. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.Type: GrantFiled: February 23, 2021Date of Patent: March 5, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter L. Collins, Thomas Charles McCarty
-
Publication number: 20240067947Abstract: Provided herein are polypeptides that are truncated modified recombinant forms of ADAMTS13, nucleic acid molecules encoding the polypeptides, drug delivery compositions and pharmaceutical compositions comprising the polypeptides, and methods of using the polypeptides and compositions (e.g., in the treatment of thrombotic thrombocytopenic purpura (TTP)).Type: ApplicationFiled: October 28, 2021Publication date: February 29, 2024Applicants: Children's Medical Center Corporation, The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Daniel S. Kohane, Juan C. Ibla, Upendra Katneni, Chava Kimchi-Sarfaty
-
Publication number: 20240069001Abstract: An in vitro release test (IVRT) method and system is provided for drug release testing. The IVRT method, referred to herein as adaptive perfusion, employ tangential-flow filtration (TFF), where released drug products that are smaller than a molecular weight cutoff (MWCO) of a membrane filter pass therethrough into the permeate. Unreleased drug products are retained by the pores of the filter and are recirculated to a retentate reservoir. Fresh media is provided to the retentate in order to maintain a constant total volume for the sample as well as to maintain sink conditions for the drug release. Drug concentration in the retentate and permeate are evaluated by in situ monitoring with one or more sensors and/or by periodic removal of aliquots from the respective reservoirs. In some embodiments, the membrane filter can be conditioned prior to use in order to improve the accuracy, precision, or both of the subsequent testing.Type: ApplicationFiled: December 20, 2021Publication date: February 29, 2024Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Xiaoming Xu, Deval Patel, Ying Zhang
-
Patent number: 11905313Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) G ectodomain are provided. Also disclosed are nucleic acids encoding the RSV G ectodomain and methods of producing the RSV G ectodomain. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for inhibiting a RSV infection in a subject by administering an effective amount of the recombinant RSV G ectodomain to the subject to produce a protective immune response.Type: GrantFiled: November 27, 2018Date of Patent: February 20, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services.Inventor: Surender Khurana
-
Patent number: 11905564Abstract: Described herein are biomarkers for HPV-associated pre-cancers and cancers such as cervical cancer and cervical intraepithelial neoplasia. The RNA binding protein (RBP) and long-noncoding RNA (lnc-RNA) biomarkers can be detected and used to diagnose HPV-associated pre-cancers and cancers. In addition, early diagnosis of HPV-associated pre-cancers and cancers can facilitate therapeutic intervention in patients, particularly in the pre-cancer stage which can delay or prevent progression to cancer.Type: GrantFiled: August 1, 2022Date of Patent: February 20, 2024Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Zhi-Ming Zheng, Junfen Xu, Jun Zhu, Yanqin Yang, Xiaohong Wang
-
Patent number: 11906528Abstract: Kits and methods to distinguish between false and true labor are provided. The kits and methods can utilize differences in abundance and/or differences in the rate of change in abundance of B7-H2, SORC2, TF, C1-Esterase Inhibitor, Ran, IMDH1 and/or PGAM1, as markers of true labor.Type: GrantFiled: November 12, 2021Date of Patent: February 20, 2024Assignees: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health & Human ServicesInventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
-
Patent number: 11903929Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.Type: GrantFiled: June 28, 2022Date of Patent: February 20, 2024Assignees: Florida State University Research Foundation, Inc., The Unites States of America, as represented by the Secretary Department of Health and Human Services, The Trustees of the University of PennsylvaniaInventors: Hengli Tang, Emily M. Lee, Wei Zheng, Ruili Huang, Miao Xu, Wenwei Huang, Khalida Shamim, Guoli Ming, Hongjun Song